A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?

Abstract

AimTo determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer.MethodsIn this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects.ResultsThe presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively.DiscussionThe inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.

COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety

“…In a study on seroprevalence against COVID-19 in cancer patients, Javadinia et al has shown that seropositivity against COVID-19 is greater in females, with higher rates in patients with breast cancer and gynecologic cancers ( 60 ). Female hormones are known to enhance the immune system, and sex steroids have been shown to correlate with different immune responses to COVID-19 ( 61 , 62 ).…”

COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status

“…This information is of great importance to target potential unvaccinated individuals in patients with decompensated cirrhosis, particularly in regions where healthcare facilities are overwhelmed with COVID-19 patients. It has been reported that immunogenicity of inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) are compromised in patients with underlying disease such as cancer patients [ 3 , 34 ]. In patients with decompensated cirrhosis, approximately one-third of the cirrhotic patients had low cellular vaccine response [ 9 ] requiring additional primary shot and booster shot to enhance immunogenicity.…”

A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers

“…Ariamanesh et al reported a higher seroconversion in younger patients with cancer than 60 years (90.9%, 90%, and 79% in patients <40 years, 40–60 years, and >60 years; respectively, p = .042) [ 19 ]. Multiple studies suggest that patients with solid malignancies are likely to have a higher seroconversion than patients with hematologic malignancies 13 , 19 , 20 , 21 . Joudi et al reported an excellent immune response (93.3%) to vaccination with minimal side effects (local pain and fever in 22.3% and 24.3% of patients, respectively) in their cohort of 160 patients with breast cancer.…”

“…Joudi et al reported an excellent immune response (93.3%) to vaccination with minimal side effects (local pain and fever in 22.3% and 24.3% of patients, respectively) in their cohort of 160 patients with breast cancer. Following vaccination, the prevalence of COVID-19 infection reduced with time (0.7%, 0%, and 0%, respectively, for the first, second, and third months of follow-up) [ 21 ]. These real-world observations support the results presented in our study.…”